ReviewExpert review of anti-infective therapy2013
Antimicrobial therapies for Q fever.
Review in Expert review of anti-infective therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 98 citations in OpenAlex.
- Efficacy of Inhalational Ciprofloxacin (Apulmiq) in an NHP Model of Q Fever.Antibiotics (Basel, Switzerland) · 2026Article
- Beyond Acute Infection: A Conceptual Framework Linking Zoonotic Bacterial Pathogens to Pulmonary Fibrosis and Lung Carcinogenesis.Biomedicines · 2026Review
- The lipid A acylation pattern of Coxiella burnetii prevents detection and clearance by the non-canonical inflammasome in primary murine macrophages.PLoS pathogens · 2026Article
- Cryo-EM reveals multiple mechanisms of ribosome inhibition by doxycycline.Nature communications · 2026Article
- Subverting Host Defense from Within: Innate Immune Modulation byPathogens (Basel, Switzerland) · 2026Review
- Inhaled Ciprofloxacin as an Alternative Treatment for Infection withAntibiotics (Basel, Switzerland) · 2026Article
- Systems biology approach unveils the cellular and molecular mechanisms of formalin-inactivated whole cell vaccine-induced protective immunity againstFrontiers in immunology · 2026Article
- A Case of Chronic Q Fever Treated With Doxycycline and Trimethoprim-Sulfamethoxazole With a Favorable Outcome.Case reports in infectious diseases · 2025Article
- Navigating Q fever: Current perspectives and challenges in outbreak preparedness.Open veterinary journal · 2024Review
- An unusual cause of headache: Expanding your differential.Clinical case reports · 2024Article
- Efficacy of rifapentine and other rifamycins againstMicrobiology spectrum · 2024Article
- Homemade pericardial bifurcated graft for Q fever-infected abdominal aortic aneurysm open repair: a case report.Frontiers in cardiovascular medicine · 2024Article
- Article
- Simultaneous LC-MS/MS method for the quantitation of Azithromycin, Hydroxychloroquine and its metabolites in SARS-CoV-2(-/ +) populations using dried blood spots.Scientific reports · 2023Article
- Macrophage infectivity potentiator protein, a peptidyl prolyl cis-trans isomerase, essential for Coxiella burnetii growth and pathogenesis.PLoS pathogens · 2023Article
- Antimicrobial resistance gene lack in tick-borne pathogenic bacteria.Scientific reports · 2023Article
- Evaluation of Alternative Doxycycline Antibiotic Regimes in an Inhalational Murine Model of Q Fever.Antibiotics (Basel, Switzerland) · 2023Article
- Vascular Complications inEJVES vascular forum · 2023Article
- Rare case of chronic Q fever myocarditis in end stage heart failure patient: A case report.World journal of cardiology · 2022Article
- Quantitative Proteomics Explore the Potential Targets and Action Mechanisms of Hydroxychloroquine.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Q fever is caused by the bacterium Coxiella burnetii and has both acute and chronic forms. The acute disease is a febrile illness often with headache and myalgia that can be self-limiting, whereas the chronic disease typically presents as endocarditis and can be life threatening. The normal therapy for the acute disease is a 2 week course of doxycycline, whereas chronic disease requires 18-24 months of doxycycline in combination with hydroxychloroquine. Alternative treatments are used for pregnant women, young children and those who cannot tolerate doxycycline. Doxycycline resistance is rare, but has been reported. Co-trimoxazole is a currently recommended alternative treatment, but quinolones, rifampin and newer macrolides may also provide some benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.